Combined Anesthesia for Laparoscopy Surgery in Gynecology
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01246323|
Recruitment Status : Unknown
Verified November 2010 by Rambam Health Care Campus.
Recruitment status was: Recruiting
First Posted : November 23, 2010
Last Update Posted : August 5, 2011
|Condition or disease||Intervention/treatment|
|Pain||Procedure: Spinal anesthesia with Fentanyl+ Morphine|
Following signing an informed consent patients who are scheduled for gynecological laparoscopy surgery for benign disease will randomized to general vs. combined general and spinal anesthesia.
During the postoperative period data regarding pain level as evaluated by visual analogue scale (VAS), number of doses of pain relief drugs, satisfaction and number of day in hospitalization will be collected from patient charts.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Combined General and Spinal Anesthesia vs. General Anesthesia for Pain Relief During Laparoscopy Gynecological Surgery|
|Study Start Date :||November 2010|
|Estimated Primary Completion Date :||November 2012|
|Estimated Study Completion Date :||December 2012|
Active Comparator: combined anesthesia
Patients will receive spinal and general anesthesia for benign laparoscopy gynecological surgery
Procedure: Spinal anesthesia with Fentanyl+ Morphine
Fentanyl 15 microgram Morphine 0.1-0.5 mg
|No Intervention: Control|
- Pain level [ Time Frame: For the first 72 hours following surgery ]Pain level will be evaluated every 4 hours from the time of surgery to discharge
- Number of doses of analgesic drugs [ Time Frame: For the first 72 hours following surgery ]Number of doses of analgesic medications will be collected from patients charts.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01246323
|Contact: Lior Lowenstein, MD, MS||050-2061434||LowensteinMD@gmail.com|
|Rambam Health Care Campus||Recruiting|
|Haifa, Israel, 31096|
|Contact: Lior Lowenstein, MD 97248542612 ext 7 email@example.com|
|Contact: Dror Segal, MD 97248542382 firstname.lastname@example.org|
|Rambam Health Care Campus||Not yet recruiting|
|Haifa, Israel, 9602|
|Contact: Lior Lowenstein, MD, MS 050-2061434 LowensteinmD@gmail.com|
|Principal Investigator: Lior Lowenstein, MD,MS|
|Study Chair:||Lior Lowenstein||Rambam Health Care Campus|